94 related articles for article (PubMed ID: 38515274)
21. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
Kyriakopoulos CE; Chen YH; Carducci MA; Liu G; Jarrard DF; Hahn NM; Shevrin DH; Dreicer R; Hussain M; Eisenberger M; Kohli M; Plimack ER; Vogelzang NJ; Picus J; Cooney MM; Garcia JA; DiPaola RS; Sweeney CJ
J Clin Oncol; 2018 Apr; 36(11):1080-1087. PubMed ID: 29384722
[TBL] [Abstract][Full Text] [Related]
22. Taxane-based Combination Therapies for Metastatic Prostate Cancer.
Corn PG; Agarwal N; Araujo JC; Sonpavde G
Eur Urol Focus; 2019 May; 5(3):369-380. PubMed ID: 29275145
[TBL] [Abstract][Full Text] [Related]
23. Nano-sized cytochrome P450 3A4 inhibitors to block hepatic metabolism of docetaxel.
Paolini M; Poul L; Berjaud C; Germain M; Darmon A; Bergère M; Pottier A; Levy L; Vibert E
Int J Nanomedicine; 2017; 12():5537-5556. PubMed ID: 28814868
[TBL] [Abstract][Full Text] [Related]
24. Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.
Oudard S; Fizazi K; Sengeløv L; Daugaard G; Saad F; Hansen S; Hjälm-Eriksson M; Jassem J; Thiery-Vuillemin A; Caffo O; Castellano D; Mainwaring PN; Bernard J; Shen L; Chadjaa M; Sartor O
J Clin Oncol; 2017 Oct; 35(28):3189-3197. PubMed ID: 28753384
[TBL] [Abstract][Full Text] [Related]
25. Lycopene, tomato products and prostate cancer-specific mortality among men diagnosed with nonmetastatic prostate cancer in the Cancer Prevention Study II Nutrition Cohort.
Wang Y; Jacobs EJ; Newton CC; McCullough ML
Int J Cancer; 2016 Jun; 138(12):2846-55. PubMed ID: 26830232
[TBL] [Abstract][Full Text] [Related]
26. The effects of lycopene on intestinal injury due to methotrexate in rats.
Yucel Y; Tabur S; Gozeneli O; Kocarslan S; Seker A; Buyukaslan H; Şavik E; Aktumen A; Ozgonul A; Uzunkoy A; Aksoy N
Redox Rep; 2016 May; 21(3):113-8. PubMed ID: 26359686
[TBL] [Abstract][Full Text] [Related]
27. Determination of CYP3A4 Inducing Properties of Compounds Using a Laboratory-Developed Cell-Based Assay.
Seah TC; Tay YL; Tan HK; Muhammad TS; Wahab HA; Tan ML
Int J Toxicol; 2015; 34(5):454-68. PubMed ID: 26268769
[TBL] [Abstract][Full Text] [Related]
28. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.
Yu EY; Li H; Higano CS; Agarwal N; Pal SK; Alva A; Heath EI; Lam ET; Gupta S; Lilly MB; Inoue Y; Chi KN; Vogelzang NJ; Quinn DI; Cheng HH; Plymate SR; Hussain M; Tangen CM; Thompson IM
J Clin Oncol; 2015 May; 33(14):1601-8. PubMed ID: 25847934
[TBL] [Abstract][Full Text] [Related]
29. Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era.
Zu K; Mucci L; Rosner BA; Clinton SK; Loda M; Stampfer MJ; Giovannucci E
J Natl Cancer Inst; 2014 Feb; 106(2):djt430. PubMed ID: 24463248
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review.
Lyman GH; Abella E; Pettengell R
Crit Rev Oncol Hematol; 2014 Jun; 90(3):190-9. PubMed ID: 24434034
[TBL] [Abstract][Full Text] [Related]
31. Circulating progenitor and mature endothelial cells in deep vein thrombosis.
Alessio AM; Beltrame MP; Nascimento MC; Vicente CP; de Godoy JA; Silva JC; Bittar LF; Lorand-Metze I; de Paula EV; Annichino-Bizzacchi JM
Int J Med Sci; 2013; 10(12):1746-54. PubMed ID: 24155660
[TBL] [Abstract][Full Text] [Related]
32. Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors.
Sessa C; Lorusso P; Tolcher A; Farace F; Lassau N; Delmonte A; Braghetti A; Bahleda R; Cohen P; Hospitel M; Veyrat-Follet C; Soria JC
Clin Cancer Res; 2013 Sep; 19(17):4832-42. PubMed ID: 23833302
[TBL] [Abstract][Full Text] [Related]
33. Resveratrol and cancer treatment: is hormesis a yet unsolved matter?
Borriello A; Bencivenga D; Caldarelli I; Tramontano A; Borgia A; Pirozzi AV; Oliva A; Della Ragione F
Curr Pharm Des; 2013; 19(30):5384-93. PubMed ID: 23394084
[TBL] [Abstract][Full Text] [Related]
34. Lycopene inhibits angiogenesis both in vitro and in vivo by inhibiting MMP-2/uPA system through VEGFR2-mediated PI3K-Akt and ERK/p38 signaling pathways.
Chen ML; Lin YH; Yang CM; Hu ML
Mol Nutr Food Res; 2012 Jun; 56(6):889-99. PubMed ID: 22707264
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy-based treatment for castration-resistant prostate cancer.
Seruga B; Tannock IF
J Clin Oncol; 2011 Sep; 29(27):3686-94. PubMed ID: 21844499
[TBL] [Abstract][Full Text] [Related]
36. Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab.
Malka D; Boige V; Jacques N; Vimond N; Adenis A; Boucher E; Pierga JY; Conroy T; Chauffert B; François E; Guichard P; Galais MP; Cvitkovic F; Ducreux M; Farace F
Ann Oncol; 2012 Apr; 23(4):919-27. PubMed ID: 21825101
[TBL] [Abstract][Full Text] [Related]
37. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.
Tzelepi V; Efstathiou E; Wen S; Troncoso P; Karlou M; Pettaway CA; Pisters LL; Hoang A; Logothetis CJ; Pagliaro LC
J Clin Oncol; 2011 Jun; 29(18):2574-81. PubMed ID: 21606419
[TBL] [Abstract][Full Text] [Related]
38. Commentary: Serum lycopene and prostate cancer progression: a re-consideration of findings from the prostate cancer prevention trial.
Giovannucci E
Cancer Causes Control; 2011 Jul; 22(7):1055-9. PubMed ID: 21573862
[TBL] [Abstract][Full Text] [Related]
39. Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel.
Uzoh CC; Holly JM; Biernacka KM; Persad RA; Bahl A; Gillatt D; Perks CM
Br J Cancer; 2011 May; 104(10):1587-93. PubMed ID: 21487405
[TBL] [Abstract][Full Text] [Related]
40. Antioxidant effects of lycopene in African American men with prostate cancer or benign prostate hyperplasia: a randomized, controlled trial.
van Breemen RB; Sharifi R; Viana M; Pajkovic N; Zhu D; Yuan L; Yang Y; Bowen PE; Stacewicz-Sapuntzakis M
Cancer Prev Res (Phila); 2011 May; 4(5):711-8. PubMed ID: 21430075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
